Theriva Biologics, Inc. (TOVX)
NYSE American · Healthcare · Biotechnology
$0.225−0.04%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $10.3M
- P/E (trailing)
- 0.3
- 52-week range
- $0.16 – $0.86
- 52-week change
- −43.90%
- EPS (trailing)
- $0.73
Fiscal year to Dec 2025
- Net income
- −$23.7M
- Diluted EPS
- −$2.08
- Free cash flow
- −$16.7M
From the company’s annual report on SEC EDGAR.
About Theriva Biologics, Inc.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications. In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics.
Headquarters: Rockville, United States · 15 employees · therivabio.com